Hannah Joseph Hospital reported a 55% jump in Profit After Tax (PAT) to ₹11.18 crore for FY26. Revenue grew 18.73% to ₹92.05 crore, with improved margins and operational efficiencies.

Hannah Joseph Hospital FY26 Results

PAT ₹11.18 crore; Revenue ₹92.05 crore

Reader Takeaway: Strong profit growth driven by revenue expansion and operational efficiency, with future potential from oncology.

What just happened

Hannah Joseph Hospital Ltd reported a robust financial performance for the fiscal year ended March 2026 (FY26). The company's Profit After Tax (PAT) surged by 55%, reaching ₹11.18 crore, up from ₹7.21 crore in FY25. Revenue from operations saw a significant increase of 18.73%, growing to ₹92.05 crore from ₹77.53 crore in the previous fiscal year.

Why this matters

The strong bottom-line growth, outpacing revenue expansion, indicates improved profitability and operational leverage. The enhanced margins, with PAT margin rising to 12.15% from 9.30%, and EBITDA margin to 27.12% from 26.47%, signal better cost management and efficiency. This performance suggests the hospital is effectively translating increased business into higher profits for shareholders.

The backstory

Hannah Joseph Hospital has demonstrated a consistent growth trend over multiple years. The company's PAT has shown a steady upward trajectory, increasing from ₹1.01 crore in FY23 to ₹11.18 crore in FY26. This sustained performance highlights the hospital's ability to expand its operations and profitability year after year.

What changes now

The hospital is set to expand into Radiation Oncology by constructing a dedicated cancer care infrastructure on an acquired land parcel. This strategic move aims to enter a high-margin service area and diversify its revenue streams. Additionally, the launch of 24/7 emergency medical services at Madurai Airport in 2026 is expected to enhance service reach and utilization.

Risks to watch

While the oncology expansion offers growth potential, it requires significant capital investment and faces execution risks. The competitive landscape in specialized healthcare services also presents a challenge. Detailed financial implications of the expansion and its ramp-up will be crucial to monitor.

Peer comparison

(No peer comparison data available in the filing.)

Context metrics (time-bound)

• Revenue from operations: ₹92.05 crore (FY26) vs ₹77.53 crore (FY25)
• EBITDA: ₹24.96 crore (FY26) vs ₹20.52 crore (FY25)
• Profit After Tax (PAT): ₹11.18 crore (FY26) vs ₹7.21 crore (FY25)
• Basic/Diluted EPS: ₹6.32 (FY26)
• EBITDA Margin: 27.12% (FY26) vs 26.47% (FY25)
• PAT Margin: 12.15% (FY26) vs 9.30% (FY25)
• ARPOB: ₹1.39 crore (FY26) vs ₹0.92 crore (FY25)
• Revenue per Bed/Day: ₹38,000 (FY26) vs ₹25,000 (FY25)
• Average Bed Occupancy: 57 Beds (FY26) vs 57 Beds (FY25)
• Capacity Utilization: 43% (FY26) vs 42.49% (FY25)

What to track next

Investors will be keen to monitor the progress of the oncology infrastructure project, including timelines, investment details, and early revenue contributions. The hospital's ability to further improve operational efficiency and patient realization metrics will also be key.